Navigation Links
Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Date:7/7/2011

t of SEGA response rate, with 35% of patients (27 of 78) receiving everolimus experiencing a 50% or greater reduction in SEGA volume (sum of volumes of all target SEGAs) relative to baseline versus 0% of patients (0 of 39) on placebo (p<0.0001)(1).

"This study, which included SEGA patients from infancy to adulthood, provides compelling evidence of the impact of everolimus in reducing SEGA size with a tolerability profile consistent with the previous everolimus trial in this treatment setting," said Dr. Sergiusz Jozwiak, a lead EXIST-1 investigator and Professor, Department of Child Neurology, The Children's Memorial Health Institute, Warsaw, Poland. "This is very good news for patients and caregivers in many countries who currently may face brain surgery as the only treatment option for growing SEGAs."

Everolimus targets mTOR, a protein that acts as an important regulator of tumor cell division, blood vessel growth and cell metabolism(9). Tuberous sclerosis complex is caused by defects in the TSC1 and/or TSC2 genes. When these genes are defective, mTOR activity is increased, which can cause uncontrolled tumor cell growth and proliferation, blood vessel growth and altered cellular metabolism, leading to the formation of non-cancerous tumors throughout the body, including the brain. By inhibiting mTOR activity in this signaling pathway, everolimus may reduce cell proliferation, blood vessel growth and glucose uptake related to SEGA associated with TSC(2,6).

"The positive results seen in the Phase III trial point to the important role of everolimus and mTOR inhibition in SEGA associated with TSC," said Herve Hoppenot, President, Novartis Oncology. "This outcome is welcome news as we continue our research efforts to fully understand the potential of this important treatment option across the wide range of disorders associated with TSC."

The Phase III study supports the findings of the Phase II study used for registration in s
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
2. GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
3. Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal
4. Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain
5. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
6. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
7. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
8. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
9. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
10. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
11. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015  Perrigo Company plc ("Perrigo") (NYSE: ... completed the acquisition of leading OTC brands from GSK ... The transaction is a clear demonstration of Perrigo,s unique ... European distribution network spanning 36 countries.  ... commented, "We are excited to complete this transaction, ...
(Date:8/28/2015)... Aug. 28, 2015 , Joint ... Ra from Biostar , Published in ,Stem Cells ... of lifespan through multiple IV administration of Adipose-derived MSC ... life expectancy found , Commercialization within 5 years ... the possibility that adult mesenchymal stem cells (MSCs) may ...
(Date:8/28/2015)... LONDON , August 28, 2015 ... approach seamlessly connects people, technologies and care ... improving outcomes and the cost of healthcare delivery ... AEX: PHIA) today announced its presence at  ESC Congress 2015 , ... Heart Model A.I. , EchoNavigator and IntelliSpace Cardiovascular, that connect ...
Breaking Medicine Technology:Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4
... Ridge Diagnostics, Inc., a neurodiagnostic company, announced that ... test for Major Depressive Disorder(MDD), will be presented during ... to Aid in Diagnosis, Treatment and Management of Major ... Meeting, May 20, 2009. The blood test, for the ...
... ATLANTA, May 20 /PRNewswire-FirstCall/ -- ... an Atlanta-based, publicly traded biopharmaceutical company developing human ... Virus) and other infectious agents, announced today that ... band Styx, has joined the GeoVax Labs awareness ...
Cached Medicine Technology:Ridge Diagnostics, Inc. Clinical Data on Blood Test for Depression Presented at American Psychiatric Association Annual Meeting 2Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine 2Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine 3Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine 4
(Date:8/28/2015)... ... August 28, 2015 , ... ... Day at the Zoo to celebrate children helping children, a thank you to ... throughout West Ohio have contributed to the United Methodist initiative to end malaria ...
(Date:8/28/2015)... Angeles, CA (PRWEB) , ... August 28, 2015 , ... ... endless journey that local pizza maker Paul LaRocco has gone through to open a ... city approval and permitting process tends to take several months, but the current process, ...
(Date:8/28/2015)... ... 28, 2015 , ... For Dallas, the time is nearing for the annual ... Tenet Health. , The American Heart Association hosts their well-known Heart Walk to raise ... together, a difference can be made. Walkers can participate in the cause and someone ...
(Date:8/28/2015)... ... 2015 , ... As reported by Medical Daily on August 22 , ... that last for two years, the longest of any cellulite reduction system currently on ... a long-lasting, effective solution for their cellulite, according to Dr. Robert Weiss, director of ...
(Date:8/28/2015)... ... August 28, 2015 , ... On May 30th, 2015, Best Drug Rehabilitation, a ... “Music With A Mission” benefit concert in Mendon, IL. Held in the Show Barn ... to support music education programs in the underfunded local school districts of Mendon at ...
Breaking Medicine News(10 mins):Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2
... Beth Israel Deaconess,Medical Center audit, BOSTON, Feb. 6 ... apply the same Sarbanes-Oxley,standards used by Boston Properties and ... of Beth Israel Deaconess Medical Center (BIDMC),according to labor ... the president and CFO of Boston Properties., 1199 ...
... The Female Health Company,(Amex: FHC ) today ... call,to discuss its operating results for the first ... on Wednesday, February 13, 2008. The Company plans,to ... the same day., Shareholders and other interested ...
... asks board member to seek restatement of Beth Israel ... Automation CEO and,director Robert Lepofsky should apply the same ... to his role as Vice,Chairperson of the board of ... (BIDMC), according to labor group 1199 SEIU,United Healthcare Workers ...
... TULSA, Okla., Feb. 6 It takes a team ... That,s the,message of an event scheduled for 10 a.m. ... a significant improvement in Oklahoma,s rates of,early childhood immunizations., ... based on,data from 2005 and 2006, the state improved ...
... Limited, BOSTON, Feb. 6 Patient-Centered Computing,and eHealth: ... will be presented under the auspices of Harvard Medical,School,s ... held,at the Omni Parker House Hotel in Boston, MA ... 2006 event that attracted 120 attendees from,throughout the United ...
... This release is also available in German . ... giant dinosaurs could have lived off more than 100 million years ... to become as large as they did. In actual fact such ... have now been published in the journal ,Proceedings of the Royal ...
Cached Medicine News:Health News:Boston Properties Executive and Board Member Should Use Sarbanes-Oxley Disclosure Rules in Non-Profit Role, Asserts 1199 SEIU 2Health News:The Female Health Company Schedules First Quarter Conference Call for February 13, 2008 2Health News:Brooks Automation Executive and Board Member Should Use Sarbanes-Oxley Disclosure Rules in Non-Profit Role, Asserts 1199 SEIU 2Health News:State Leaders Recognize Oklahoma's Improvement in Immunization Rankings 2Health News:Innovative eHealth Course to Take Place March 28-30 in Boston, Massachusetts 2Health News:Bonn scientists simulate dinosaur digestion in the lab 2Health News:Bonn scientists simulate dinosaur digestion in the lab 3